Results from all these studies are expected next year.Īlthough Kite is one of the major players in the field of immunotherapy, there are many others, both big and small, looking to develop and bring their own immunotherapy treatments to market. Kite is also evaluating KTE-C19 in the phase II ZUMA-2 study in patients with relapsed/refractory mantle cell lymphoma (MCL), and two other pivotal studies (phase I/II) for acute lymphoblastic leukemia (ALL), comprising ZUMA-3 for adult ALL and ZUMA-4 for pediatric ALL. All these diseases are types of aggressive non-Hodgkin’s lymphoma (NHL). KTE-C19, is currently in a pivotal phase of the phase I-II ZUMA-1 study on patients with refractory DLBCL, including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). The first patient in the ZUMA-6 study was enrolled last month. While the phase Ib portion of the study will evaluate the safety of KTE-C19 and atezolizumab given in a sequence, the phase II portion will mainly assess the combination’s safety and efficacy. The ZUMA-6 study is a single-arm, open-label, multi-center study. KTE-C19 is an investigational therapy that engineers the patient's T-cells to express a CAR to target the antigen CD19. Note that Kite has inked the collaboration with Genentech, a member of the Roche Holding AG RHHBY, this March, with an aim to evaluate the safety and efficacy of the combination therapy. KITE announced the initiation of ZUMA-6, a phase Ib/II combination study on its lead pipeline candidate, KTE-C19, in combination Genentech’s Tecentriq (atezolizumab), for the treatment of chemorefractory diffuse large B-cell lymphoma (DLBCL).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |